SCHEMBL15850091

SCHEMBL15850091

CC(C)(C)ON1CCN(c2ccc(NC(=O)c3cc(-c4ccncc4)c[nH]c3=O)cc2)CC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITK Q08881 5/20 0.73
▸ ALK Q9UM73 6/20 0.57
▸ INSR P06213 5/20 0.54
▸ FLT3 P36888 4/20 0.54
▸ ABL1 P00519 3/20 0.54
▸ NPM1 P06748 2/20 0.54
▸ BCR P11274 2/20 0.54
▸ IGF1R P08069 1/20 0.54
▸ TTK P33981 3/20 0.53
▸ AURKB Q96GD4 3/20 0.53
▸ INCENP Q9NQS7 3/20 0.53
▸ AURKA O14965 2/20 0.53
▸ KIT P10721 3/20 0.50
▸ SRC P12931 3/20 0.50
▸ NPY2R P49146 1/20 0.43
▸ MET P08581 1/20 0.42
▸ MST1R Q04912 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ ABCB1 P08183 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10063195 0.88 ITK (0.70) ITKALKINSRFLT3ABL1
SCHEMBL10063188 0.87 ITK (0.81) ITKALKINSRFLT3ABL1
SCHEMBL10063186 0.85 ITK (1.00) ITKALKINSRFLT3ABL1
SCHEMBL10063189 0.84 ITK (0.77) ITKALKINSRFLT3ABL1
SCHEMBL10063184 0.84 ITK (0.83) ITKALKINSRFLT3ABL1
SCHEMBL10063196 0.84 ITK (0.83) ITKALKINSRFLT3ABL1
SCHEMBL10063194 0.83 ITK (0.81) ITKALKINSRFLT3ABL1
SCHEMBL10081134 0.82 ITK (0.70) ITKALKINSRFLT3ABL1
SCHEMBL10063126 0.78 ITK (0.67) ITKALKINSRFLT3TTK
SCHEMBL10063120 0.76 ITK (0.64) ITKALKINSRTTKAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831168-B1 PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES. VERTEX PHARMA (US) 2014-07-02 — — EP disclosed
Send feedback